This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Data For Multiple Incyte Cancer Programs To Be Presented At The 2014 American Society Of Clinical Oncology (ASCO) Meeting

Incyte Corporation (Nasdaq: INCY) today announced that new data from its lead cancer programs focused on onco-inflammation, immuno-oncology and myeloproliferative neoplasms will be presented at the 50 th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from May 30 to June 3, 2014, in Chicago.

Data to be presented on June 2 include full results from RECAP, the Phase II trial of ruxolitinib in combination with capecitabine in metastatic pancreatic cancer. This proof-of-concept trial was designed to evaluate the benefits of targeting local and systemic inflammation that adversely impact patient outcomes in pancreatic cancer and many other cancers. Topline results from RECAP, announced in August 2013, showed an overall survival benefit in a pre-specified subgroup analysis of patients. This subgroup consisted of patients with increased levels of serum C-reactive protein (CRP), a well-characterized and readily measurable marker of systemic inflammation.

Also being presented on June 2 are preliminary findings from a Phase I/II study of Incyte’s IDO1 inhibitor, INCB24360, in combination with ipilimumab in patients with metastatic melanoma. This trial was designed to examine potential synergy with other cancer immunotherapies and lay the groundwork for future potential combinations with INCB24360.

On June 3, full results will be presented from the pivotal Phase III RESPONSE trial of ruxolitinib in patients with uncontrolled polycythemia vera (PV), building upon Incyte’s efforts to improve the lives of patients with myeloproliferative neoplasms. RESPONSE is the first Phase III study to evaluate a JAK inhibitor as a treatment for patients with PV. In March 2014, Incyte announced that the RESPONSE trial met its primary endpoint.

“These three studies showcase several of the innovative therapies that comprise Incyte’s growing oncology pipeline, including first-in-class compounds in the areas of onco-inflammation and immuno-oncology, which we believe have the potential to transform the way cancer is treated,” stated Hervé Hoppenot, President and Chief Executive Officer, Incyte. “We look forward to sharing the results of these studies in a prestigious oncology forum such as ASCO.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs